Oncolytic parvoviruses: from basic virology to clinical applications

Area of Science:

• Virology
• Oncology
• Gene Therapy

Background:

• Parvoviridae family members, including H-1PV, demonstrate natural anticancer activity.
• These viruses are nonpathogenic to humans, supporting their therapeutic potential.

Purpose of the Study:

• To review the antineoplastic properties of parvoviruses.
• To discuss the development of novel parvovirus-based anticancer strategies.
• To address challenges in clinical applications of oncolytic parvoviruses.

Main Methods:

• Review of existing studies on parvovirus biology and anticancer activity.
• Discussion of second and third-generation parvovirus vectors.
• Exploration of combination therapies with other anticancer agents.

Main Results:

• H-1PV is under clinical evaluation for glioblastoma multiforme safety and efficacy.
• Parvoviruses show promise as oncolytic agents.
• Enhanced specificity and efficacy are being developed through novel strategies.

Conclusions:

• Understanding parvovirus life-cycle and cellular interactions is crucial for improving oncolytic therapies.
• Further development of parvovirus-based treatments may improve clinical outcomes for cancer patients.